Alamar Biosciences, Inc. · NASDAQ:ALMR
Qiming Corporate GP VI, Ltd. sold 280,458 Alamar Biosciences, Inc. shares (Form 4)
Traded Oct 23 to Oct 26, 2026 · Filed Oct 27, 2026
From Oct 23 to Oct 26, 2026, Qiming Corporate GP VI, Ltd. (10% owner) sold 280,458 Alamar Biosciences, Inc. shares at an average US$30.56 for US$8.57M, leaving 1,738,295 shares. Filed Oct 27, 2026 (Form 4).
- Sold
- 280,458 shares
- Price
- US$30.56 average (US$29.35 to US$31.07)
- Value
- US$8.57M
- Holding after
- 1,738,295 shares (held indirectly)
- Trading plan
- No
- Role
- 10% owner
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 23, 2026 | Common Stock | Sale | 107 | US$29.35 | 172,231 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 832 | US$30.23 | 171,399 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 1,646 | US$30.85 | 169,753 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 3,975 | US$29.35 | 6,400,806 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 30,921 | US$30.23 | 6,369,885 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 61,191 | US$30.85 | 6,308,694 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 928 | US$29.35 | 1,493,506 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 7,215 | US$30.23 | 1,486,291 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 14,277 | US$30.85 | 1,472,014 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 1,110 | US$29.35 | 1,788,073 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 8,638 | US$30.23 | 1,779,435 | Indirect |
| Oct 23, 2026 | Common Stock | Sale | 17,094 | US$30.85 | 1,762,341 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 2,313 | US$30.52 | 167,440 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 2 | US$31.07 | 167,438 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 86,008 | US$30.52 | 6,222,686 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 70 | US$31.07 | 6,222,616 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 20,069 | US$30.52 | 1,451,945 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 16 | US$31.07 | 1,451,929 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 24,027 | US$30.52 | 1,738,314 | Indirect |
| Oct 26, 2026 | Common Stock | Sale | 19 | US$31.07 | 1,738,295 | Indirect |
Source
Download original · View original at SEC
Related
- Alamar Biosciences, Inc.
- Qiming Corporate GP VI, Ltd.
- Alamar Biosciences, Inc. shareholders
- Form 4 · Qiming Corporate GP VI, Ltd. · Nov 13, 2026
- Form 4 · Qiming Corporate GP VI, Ltd. · Nov 5, 2026
- Form 4 · Qiming Corporate GP VI, Ltd. · Nov 3, 2026
- Form 4 · Qiming Corporate GP VI, Ltd. · Oct 29, 2026
- Form 4 · Qiming Corporate GP VI, Ltd. · Oct 23, 2026
- Schedule 13G · Yuling Luo · Aug 13, 2026
- Schedule 13G · Qiming Corporate GP VI, Ltd. · Aug 11, 2026
- Schedule 13D/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Jul 7, 2026
- Schedule 13G · Daqing Cai · Jul 2, 2026
- Schedule 13D · Nicholas Naclerio · Apr 23, 2026